IPP Bureau
Venus Remedies secures GMP certification for antibiotic carbapenem facility in Moldova
By IPP Bureau - January 01, 2025
Expects to unlock further opportunities in the Moldovan market, contributing anticipated sales of $300,000 in 2025 and approximately $700,000–$800,000 in 2026
Anthem Biosciences files DRHP for Rs. 3,395 crore IPO
By IPP Bureau - January 01, 2025
Anthem’s business comprises of CRDMO services and the manufacture and sale of Specialty Ingredients
Sanofi acquires rights to develop and commercialize Aficamten in Greater China
By IPP Bureau - January 01, 2025
In 2020, CORXEL acquired the rights to develop and commercialize aficamten in Greater China
Merck inks agreement with Hansoh Pharma for investigational Oral GLP-1 receptor agonist
By IPP Bureau - January 01, 2025
Hansoh Pharma has granted Merck an exclusive global license to develop, manufacture and commercialize HS-10535
Immedica to acquire biopharmaceutical company Marinus Pharmaceuticals
By IPP Bureau - December 31, 2024
Immedica to commence a cash tender offer to acquire all issued and outstanding shares of Marinus for an enterprise value of approximately US$ 151 million
Senores Pharmaceuticals IPO lists at 53% premium
By IPP Bureau - December 31, 2024
The company's portfolio includes 21 commercialized products, 19 approved ANDAs, 4 CGT designations, 6 filed ANDAs, and 45 products in its pipeline
Lupin acquires Huminsulin from Lilly to enhance diabetes portfolio
By IPP Bureau - December 31, 2024
The huminsulin range of products is indicated for the treatment of type 1 and type 2 diabetes mellitus to improve blood sugar control in both adults and childre
IDEAYA Biosciences enters license with Hengrui Pharma for a novel phase 1 DLL3 Topo-I-Payload ADC targeting SCLC and NET solid tumors
By IPP Bureau - December 31, 2024
Exclusive global license outside of Greater China for SHR-4849, a Phase 1 DLL3-targeting Topo-I-payload antibody drug conjugate (ADC)
Cupid strengthens board with appointment of four new directors
By IPP Bureau - December 31, 2024
Smeeta Bhatkal, Santosh Desai and Akshay Kumar join as Independent Directors; Shaina NC as Non-Executive Director
Cenexi's Fontenay manufacturing facility receives 10 observations in ANSM inspection
By IPP Bureau - December 30, 2024
Cenexi is committed to working closely with the ANSM to address the observations
Reliance acquires Karkinos Healthcare for Rs. 375 Cr
By IPP Bureau - December 29, 2024
Karkinos is in the business of providing technology-driven, innovative solutions for the early detection, diagnosis, and management of cancer.
Sterling Biotech and Zydus Lifesciences agree to extend completion of business transfer
By IPP Bureau - December 28, 2024
Zydus Lifesciences and SBL have mutually decided to extend the date of closing upto March 31, 2025
Department of Biotechnology hosts webinar on biomanufacturing of enzymes
By IPP Bureau - December 28, 2024
The session focused on “Biomanufacturing of Enzymes,” a critical domain under the BioE3 Policy.
Shilpa Medicare's Unit IV receives Eurasia GMP approval
By IPP Bureau - December 28, 2024
Both units of Shilpa Medicare (Unit IV and Unit VII), have now received GMP approval from Eurasia
Fortis Healthcare appoints Leo Puri as Chairman of the Board
By IPP Bureau - December 28, 2024
Puri is an accomplished leader and financial sector veteran with over four decades of experience
